株式会社グローバルインフォメーション
TEL: 044-952-0102
市場調査レポート

慢性腰痛(CLBP) - 市場の洞察、疫学および2028年までの予測

Chronic Lower Back Pain (CLBP) - Market Insights, Epidemiology and Market Forecast-2028

発行 DelveInsight Business Research LLP 商品コード 888159
出版日 ページ情報 英文 301 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=109.25円で換算しております。
Back to Top
慢性腰痛(CLBP) - 市場の洞察、疫学および2028年までの予測 Chronic Lower Back Pain (CLBP) - Market Insights, Epidemiology and Market Forecast-2028
出版日: 2019年07月01日 ページ情報: 英文 301 Pages
概要

当レポートでは世界の慢性腰痛(CLBP)市場について調査しており、米国・EU・日本別の疫学調査、競合情勢、主要7ヶ国市場分析、市場予測および成長要因などの情報を提供しています。

目次

第1章 主な洞察

第2章 慢性腰痛(CLBP)市場の概要

  • 2017年におけるCLBPの市場(%)分布
  • 2028年におけるCLBPの市場(%)分布

第3章 慢性腰痛(CLBP):疾患の背景と概要

  • イントロダクション
  • 兆候と症状
  • 原因と危険因子
  • 慢性腰痛の遺伝
  • 病態生理学
    • 変性カスケード
    • CLBPの原因の背後にあるメカニズム的要因
    • 神経可塑性と中枢性感作
    • CLBPにおける結合組織リモデリング
    • 感覚求心性調節に対する結合組織病理学の影響
    • CLBPと結合組織リモデリング
    • 病態生理学的モデル
  • 痛みの種類
    • 椎間板由来の痛み
    • 腰椎狭窄
    • 仙腸痛
    • 椎間関節痛
    • 歯根疼痛
    • 筋肉痛
  • 診断
    • 病歴
    • 身体検査
    • イメージングガイドライン
    • 痛みの評価

第4章 疫学と患者人口

  • 主な調査結果
  • 主要7ヶ国における慢性腰痛の総有病人口
  • 主要7ヶ国における慢性腰痛の総診断された優勢な人口
  • 主要7ヶ国における慢性腰痛の性特異的診断有病率
  • 主要7ヶ国における慢性腰痛の年齢別診断罹患率
  • 主要7ヶ国における慢性腰痛の重症度特異的診断有病率

第5章 米国の疫学

  • 仮定と理論的根拠
  • 米国における慢性腰痛の総有病人口
  • 米国における慢性腰痛の総診断流行人口
  • 米国における慢性腰痛の性特異的診断有病率
  • 米国における慢性腰痛の年齢別診断罹患率
  • 米国におけるCLBPの重症度特異的診断有病率
  • 米国の異なるクラス別処方薬を服用しているCLBP患者の数
  • 米国における低用量、高用量および過量投与別オピオイド服用中のCLBP患者の数

第6章 EU5か国の疫学

  • ドイツ疫学
    • 仮定と理論的根拠
    • ドイツにおける慢性腰痛の総有病人口
    • ドイツにおける慢性腰痛の総診断流行人口
    • ドイツにおける慢性腰痛の性特異的診断有病率
    • ドイツにおける慢性腰痛の年齢別診断罹患率
    • ドイツにおけるCLBPの重症度特異的診断有病率
    • ドイツの異なるクラス別処方薬を服用しているCLBP患者の数
    • ドイツにおける低用量、高用量および過量投与別オピオイド服用中のCLBP患者の数
  • フランス疫学
    • 仮定と理論的根拠
  • イタリア疫学
  • スペイン疫学
  • 英国疫学
    • 英国における慢性腰痛の総有病人口
    • 英国における慢性腰痛の総診断された優勢な人口
    • 英国における慢性腰痛の性特異的診断有病率
    • 英国における慢性腰痛の年齢別診断罹患率
    • 英国におけるCLBPの重症度特異的診断有病率
    • 英国の異なるクラス別処方薬を服用しているCLBP患者の数
    • 英国における低用量、高用量および過量投与別オピオイド服用中のCLBP患者の数

第7章 日本の疫学

  • 仮定と理論的根拠
  • 日本における慢性腰痛の総有病人口
  • 日本における慢性腰痛の総診断流行人口
  • 日本における慢性腰痛の性特異的診断有病率
  • 日本における慢性腰痛の年齢別診断罹患率
  • 日本におけるCLBPの重症度特異的診断有病率
  • 日本における異なるクラス別処方薬を服用しているCLBP患者の数
  • 日本における低用量、高用量および過量投与別オピオイド服用中のCLBP患者の数

第8章 治療アルゴリズム、現在の治療、そして医療行為

  • 非薬理学的治療
  • 薬理学的治療
    • 非オピオイド鎮痛薬
    • オピオイド鎮痛薬
    • トラマドールW
    • 抗うつ薬
    • 筋弛緩剤
  • 治療アルゴリズム

第9章 慢性腰痛に対するガイドラインの提案

  • NICEガイドライン
    • 推奨
  • 疾病管理予防センター(CDC)ガイドライン
    • 推奨
  • 米国内科学会(ACP)ガイドライン

第10章 満たされていないニーズ

第11章 市販製品

  • Cymbalta (Duloxetine): Eli Lilly and Company
    • 製品説明
    • 規制のマイルストーン
    • 臨床開発
    • 安全性と効能
    • 長所と短所
    • 製品プロファイル
  • Xtampza: Collegium Pharmaceutical
    • 臨床開発
  • Butrans(buprenorphine):Purdue Pharma
  • Belbuca:BioDelivery Sciences International

第12章 新たな治療法

  • 主要な競合製品
  • NKTR-181: Nektar Therapeutics
    • 薬の説明
    • その他の開発活動
    • 臨床開発
    • 安全性と効能
    • 製品プロファイル
  • Tanezumab: Eli Lilly/Pfizer
    • 製品説明
  • Fasinumab: Regeneron Pharmaceuticals/ Teva Pharmaceuticals
  • MPC-06-ID (Rexlemestrocel-L): Mesoblast
  • CAM2038:Braeburn Pharmaceuticals / Camurus
  • Egalet-002: Egalet Corporation
  • ALLOD-2: Allodynic Therapeutics
  • Clonidine Micropellets (STX-051): Sollis Therapeutics
    • 製品開発活動
    • 臨床開発
  • GRT6005:Grunenthal GmbH
    • その他の開発活動
    • 製品プロファイル
  • AB001: Frontier Biotechnologies
    • その他の発達活動
    • 安全性と効能
  • ASP7962: Astellas Pharma Europe B.V. (アステラス製薬株式会社)
  • AXS-02 (disodium zoledronate tetrahydrate): Axsome Therapeutics
    • 薬の説明
    • その他の開発活動
  • YH14618: Yuhan Corporation
  • IDCT:DiscGenics
    • 臨床開発活動
  • SP-102: Semnur Pharmaceuticals
  • SX600:SpineThera

第13章 慢性腰痛(CLBP):主要7ヶ国市場分析

  • 主な調査結果
  • 主要7ヶ国における慢性腰痛の市場規模
  • 主要7ヶ国における治療法別慢性腰痛の市場規模
  • 主要7ヶ国諸国におけるオピオイドの流行

第14章 米国:市場の見通し

  • 米国市場規模
    • 米国における慢性腰痛の総市場規模
    • 米国における治療法別慢性腰痛の市場規模

第15章 欧州5ヶ国諸国:市場の見通し

  • ドイツ市場規模
    • ドイツにおける慢性腰痛の総市場規模
    • ドイツにおける治療法別慢性腰痛の市場規模
  • フランス市場規模
  • イタリア市場規模
  • スペイン市場規模
  • 英国の市場規模
    • 英国における慢性腰痛の総市場規模
    • 英国における治療法別慢性腰痛の市場規模

第16章 日本市場の見通し

  • 日本の市場規模
    • 日本における慢性腰痛の総市場規模
    • 日本における治療法別慢性腰痛の市場規模

第17章 市場の成長要因

第18章 市場の障壁

第19章 付録

  • レポート調査方法

第20章 DelveInsightのサービス内容

第21章 免責事項

第22章 DelveInsightについて

図表

List of Tables

  • Table 1: Risk factors for occurrence and chronicity of low back pain
  • Table 2: Cause of Muscle connective tissue fibrosis
  • Table 3: Total Prevalent Population of Chronic Lower Back Pain in the 7MM (2017-2028)
  • Table 4: Total Diagnosed Prevalent Population of Chronic Lower Back Pain in the 7MM (2017-2028)
  • Table 5: Gender-Specific Diagnosed Prevalence of Chronic Lower Back Pain in the 7MM (2017-2028)
  • Table 6: Age-Specific Diagnosed Prevalence of Chronic Lower Back Pain in the 7MM (2017-2028)
  • Table 7: Severity-Specific Diagnosed Prevalence of CLBP in the 7MM (2017-2028)
  • Table 8: Total Prevalent Population of Chronic Lower Back Pain in the US (2017-2028)
  • Table 9: Total Diagnosed Prevalent Population of Chronic Lower Back Pain in the US (2017-2028)
  • Table 10: Gender-Specific Diagnosed Prevalence of Chronic Lower Back Pain in the US (2017-2028)
  • Table 11: Age-Specific Diagnosed Prevalence of Chronic Lower Back Pain in the United States (2017-2028)
  • Table 12: Severity-Specific Diagnosed Prevalence of CLBP in the US (2017-2028)
  • Table 13: Number of CLBP Patients on Prescription Medications by different Class in the US (2017-2028)
  • Table 14: Number of CLBP Patients on Opioids by low dose, high dose & Overdose in the US (2017-2028)
  • Table 15: Total Prevalent Population of Chronic Lower Back Pain in Germany (2017-2028)
  • Table 16: Total Diagnosed Prevalent Population of Chronic Lower Back Pain in Germany (2017-2028)
  • Table 17: Gender-Specific Diagnosed Prevalence of Chronic Lower Back Pain in Germany (2017-2028)
  • Table 18: Age-Specific Diagnosed Prevalence of Chronic Lower Back Pain in Germany (2017-2028)
  • Table 19: Severity-Specific Diagnosed Prevalence of CLBP in Germany (2017-2028)
  • Table 20: Number of CLBP Patients on Prescription Medications by different Class in Germany (2017-2028)
  • Table 21: Number of CLBP Patients on Opioids by low dose, high dose & Overdose in Germany (2017-2028)
  • Table 22: Total Prevalent Population of Chronic Lower Back Pain in France (2017-2028)
  • Table 23: Total Diagnosed Prevalent Population of Chronic Lower Back Pain in France (2017-2028)
  • Table 24: Gender-Specific Diagnosed Prevalence of Chronic Lower Back Pain in France (2017-2028)
  • Table 25: Age-Specific Diagnosed Prevalence of Chronic Lower Back Pain in France (2017-2028)
  • Table 26: Severity-Specific Diagnosed Prevalence of syndromic CLBP in France (2017-2028)
  • Table 27: Number of CLBP Patients on Prescription Medications by different Class in France (2017-2028)
  • Table 28: Number of CLBP Patients on Opioids by low dose, high dose & Overdose in France (2017-2028)
  • Table 29: Total Prevalent Population of Chronic Lower Back Pain in Italy (2017-2028)
  • Table 30: Total Diagnosed Prevalent Population of Chronic Lower Back Pain in Italy (2017-2028)
  • Table 31: Gender-Specific Diagnosed Prevalence of Chronic Lower Back Pain in Italy (2017-2028)
  • Table 32: Age-Specific Diagnosed Prevalence of Chronic Lower Back Pain in Italy (2017-2028)
  • Table 33: Severity-Specific Diagnosed Prevalence of CLBP in Italy (2017-2028)
  • Table 34: Number of CLBP Patients on Prescription Medications by different Class in Italy (2017-2028)
  • Table 35: Number of CLBP Patients on Opioids by low dose, high dose & Overdose in Italy (2017-2028)
  • Table 36: Total Prevalent Population of Chronic Lower Back Pain in Spain (2017-2028)
  • Table 37: Total Diagnosed Prevalent Population of Chronic Lower Back Pain in Spain (2017-2028)
  • Table 38: Gender-Specific Diagnosed Prevalence of Chronic Lower Back Pain in Spain (2017-2028)
  • Table 39: Age-Specific Diagnosed Prevalence of Chronic Lower Back Pain in Spain (2017-2028)
  • Table 40: Severity-Specific Diagnosed Prevalence of CLBP in Spain (2017-2028)
  • Table 41: Number of CLBP Patients on Prescription Medications by different Class in Spain (2017-2028)
  • Table 42: Number of CLBP Patients on Opioids by low dose, high dose & Overdose in Spain (2017-2028)
  • Table 43: Total Prevalent Population of Chronic Lower Back Pain in the United Kingdom (2017-2028)
  • Table 44: Total Diagnosed Prevalent Population of Chronic Lower Back Pain in the United Kingdom (2017-2028)
  • Table 45: Gender-Specific Diagnosed Prevalence of Chronic Lower Back Pain in the United Kingdom (2017-2028)
  • Table 46: Age-Specific Diagnosed Prevalence of Chronic Lower Back Pain in the United Kingdom (2017-2028)
  • Table 47: Severity-Specific Diagnosed Prevalence of CLBP in the UK (2017-2028)
  • Table 48: Number of CLBP Patients on Prescription Medications by different Class in the UK (2017-2028)
  • Table 49: Number of CLBP Patients on Opioids by low dose, high dose & Overdose in the UK (2017-2028)
  • Table 50: Total Prevalent Population of Chronic Lower Back Pain in Japan (2017-2028)
  • Table 51: Total Diagnosed Prevalent Population of Chronic Lower Back Pain in Japan (2017-2028)
  • Table 52: Gender-Specific Diagnosed Prevalence of Chronic Lower Back Pain in Japan (2017-2028)
  • Table 53: Age-Specific Diagnosed Prevalence of Chronic Lower Back Pain in Japan (2017-2028)
  • Table 54: Severity-Specific Diagnosed Prevalence of CLBP in Japan (2017-2028)
  • Table 55: Number of CLBP Patients on Prescription Medications by different Class in Japan (2017-2028)
  • Table 56: Number of CLBP Patients on Opioids by low dose, high dose & Overdose in Japan (2017-2028)
  • Table 57: Summary of the efficacy of physical treatments for chronic LBP
  • Table 58: The American College of Physicians Guideline Grading System
  • Table 59: Cymbalta, Clinical Trial Description, 2019
  • Table 60: Xtampza ER, Clinical Trial Description, 2019
  • Table 61: Buprenorphine, Clinical Trial Description, 2019
  • Table 62: Belbuca, Clinical Trial Description, 2019
  • Table 63: Key Cross Competition: Emerging Therapies
  • Table 64: Key Cross Competition: Emerging Therapies (Continued)
  • Table 65: Key Cross Competition: Emerging Therapies (Continued)
  • Table 66: Key Cross Competition: Emerging Therapies (Continued)
  • Table 67: NKTR-181, Clinical Trial Description, 2019
  • Table 68: Tanezumab, Clinical Trial Description 2019
  • Table 69: Fasinumab, Clinical Trial Description, 2019
  • Table 70: Rexlemestrocel-L, Clinical Trial Description, 2019
  • Table 71: CAM2038, Clinical Trial Description, 2019
  • Table 72: Egalet-002, Clinical Trial Description, 2019
  • Table 73: ALLOD-2, Clinical Trial Description, 2019
  • Table 74: Clonidine Micropellets, Clinical Trial Description, 2019
  • Table 75: GRT6005, Clinical Trial Description, 2019
  • Table 76: AB001, Clinical Trial Description, 2019
  • Table 77: ASP7962, Clinical Trial Description, 2019
  • Table 78: AXS-02, Clinical Trial Description, 2019
  • Table 79: YH14618, Clinical Trial Description, 2019
  • Table 80: IDCT, Clinical Trial Description, 2019
  • Table 81: SP-102, Clinical Trial Description, 2019
  • Table 82: SX600, Clinical Trial Description, 2019
  • Table 83: Market Size of Chronic Lower Back Pain in 7MM in USD Million (2017-2028)
  • Table 84: Market Size of Chronic Lower Back Pain by therapies in the 7MM, in USD Million (2017-2028)
  • Table 85: Expected Launch Date of Emerging Drugs in the United States
  • Table 86: The US Market Size of Chronic Lower Back Pain in USD Million (2017-2028)
  • Table 87: Market Size of Chronic Lower Back Pain by therapies in the United States, in USD Million (2017-2028)
  • Table 88: Expected Launch Date of Emerging Drugs in Europe
  • Table 89: Germany Market Size of Chronic Lower Back Pain in USD Million (2017-2028)
  • Table 90: Market Size of Chronic Lower Back Pain by therapies in Germany, in USD Million (2017-2028)
  • Table 91: France Market Size of Chronic Lower Back Pain in USD Million (2017-2028)
  • Table 92: Market Size of Chronic Lower Back Pain by therapies in France, in USD Million (2017-2028)
  • Table 93: Italy Market Size of Chronic Lower Back Pain in USD Million (2017-2028)
  • Table 94: Market Size of Chronic Lower Back Pain by therapies in Italy, in USD Million (2017-2028)
  • Table 95: Spain Market Size of Chronic Lower Back Pain in USD Million (2017-2028)
  • Table 96: Market Size of Chronic Lower Back Pain by therapies in Spain, in USD Million (2017-2028)
  • Table 97: The UK Market Size of Chronic Lower Back Pain in USD Million (2017-2028)
  • Table 98: Market Size of Chronic Lower Back Pain by therapies in the United Kingdom, in USD Million (2017-2028)
  • Table 99: Expected Launch Date of Emerging Drugs in Japan
  • Table 100: Japan Market Size of Chronic Lower Back Pain in USD Million (2017-2028)
  • Table 101: Market Size of Chronic Lower Back Pain by therapies in Japan, in USD Million (2017-2028)

List of Figures

  • Figure 1: Types of Lower Back Pain
  • Figure 2: Signs and Symptoms of CLBP
  • Figure 3: Pathophysiological model for chronic low back pain linking somatic and behavioral components
  • Figure 4: Relationship describing therapeutic inventions and pathogenic mechanism
  • Figure 5: Types of Pain involved in CLBP mechanism
  • Figure 6: Definitions of Chronic Lower Back Pain
  • Figure 7: Total Prevalent Population of Chronic Lower Back Pain in the 7MM (2017-2028)
  • Figure 8: Total Diagnosed Prevalent Population of Chronic Lower Back Pain in the 7MM (2017-2028)
  • Figure 9: Gender-Specific Diagnosed Prevalence of Chronic Lower Back Pain in the 7MM (2017-2028)
  • Figure 10: Age-Specific Diagnosed Prevalence of Chronic Lower Back Pain in the 7MM (2017-2028)
  • Figure 11: Severity-Specific Diagnosed Prevalence of CLBP in the 7MM (2017-2028)
  • Figure 12: Total Prevalent Population of Chronic Lower Back Pain in the US (2017-2028)
  • Figure 13: Total Diagnosed Prevalent Population of Chronic Lower Back Pain in the US (2017-2028)
  • Figure 14: Gender-Specific Diagnosed Prevalence of Chronic Lower Back Pain in the US (2017-2028)
  • Figure 15: Age-Specific Diagnosed Prevalence of Chronic Lower Back Pain in the United States (2017-2028)
  • Figure 16: Severity-Specific Diagnosed Prevalence of CLBP in the US (2017-2028)
  • Figure 17: Number of CLBP Patients on Prescription Medications by different Class in the US (2017-2028)
  • Figure 18: Number of CLBP Patients on Opioids by low dose, high dose & Overdose in the US (2017-2028)
  • Figure 19: Total Prevalent Population of Chronic Lower Back Pain in Germany (2017-2028)
  • Figure 20: Total Diagnosed Prevalent Population of Chronic Lower Back Pain in Germany (2017-2028)
  • Figure 21: Gender-Specific Diagnosed Prevalence of Chronic Lower Back Pain in Germany (2017-2028)
  • Figure 22: Age-Specific Diagnosed Prevalence of Chronic Lower Back Pain in Germany (2017-2028)
  • Figure 23: Severity-Specific Diagnosed Prevalence of CLBP in Germany (2017-2028)
  • Figure 24: Number of CLBP Patients on Prescription Medications by different Class in Germany (2017-2028)
  • Figure 25: Number of CLBP Patients on Opioids by low dose, high dose & Overdose in Germany (2017-2028)
  • Figure 26: Total Prevalent Population of Chronic Lower Back Pain in France (2017-2028)
  • Figure 27: Total Diagnosed Prevalent Population of Chronic Lower Back Pain in France (2017-2028)
  • Figure 28: Gender-Specific Diagnosed Prevalence of Chronic Lower Back Pain in France (2017-2028)
  • Figure 29: Age-Specific Diagnosed Prevalence of Chronic Lower Back Pain in France (2017-2028)
  • Figure 30: Severity-Specific Diagnosed Prevalence of CLBP in France (2017-2028)
  • Figure 31: Number of CLBP Patients on Prescription Medications by different Class in France (2017-2028)
  • Figure 32: Number of CLBP Patients on Opioids by low dose, high dose & Overdose in France (2017-2028)
  • Figure 33: Total Prevalent Population of Chronic Lower Back Pain in Italy (2017-2028)
  • Figure 34: Total Diagnosed Prevalent Population of Chronic Lower Back Pain in Italy (2017-2028)
  • Figure 35: Gender-Specific Diagnosed Prevalence of Chronic Lower Back Pain in Italy (2017-2028)
  • Figure 36: Age-Specific Diagnosed Prevalence of Chronic Lower Back Pain in Italy (2017-2028)
  • Figure 37: Severity-Specific Diagnosed Prevalence of CLBP in Italy (2017-2028)
  • Figure 38: Number of CLBP Patients on Prescription Medications by different Class in Italy (2017-2028)
  • Figure 39: Number of CLBP Patients on Opioids by low dose, high dose & Overdose in Italy (2017-2028)
  • Figure 40: Total Prevalent Population of Chronic Lower Back Pain in Spain (2017-2028)
  • Figure 41: Total Diagnosed Prevalent Population of Chronic Lower Back Pain in Spain (2017-2028)
  • Figure 42: Gender-Specific Diagnosed Prevalence of Chronic Lower Back Pain in Spain (2017-2028)
  • Figure 43: Age-Specific Diagnosed Prevalence of Chronic Lower Back Pain in Spain (2017-2028)
  • Figure 44: Severity-Specific Diagnosed Prevalence of CLBP in Spain (2017-2028)
  • Figure 45: Number of CLBP Patients on Prescription Medications by different Class in Spain (2017-2028)
  • Figure 46: Number of CLBP Patients on Opioids by low dose, high dose & Overdose in Spain (2017-2028)
  • Figure 47: Total Prevalent Population of Chronic Lower Back Pain in the United Kingdom (2017-2028)
  • Figure 48: Total Diagnosed Prevalent Population of Chronic Lower Back Pain in the United Kingdom (2017-2028)
  • Figure 49: Gender-Specific Diagnosed Prevalence of Chronic Lower Back Pain in the United Kingdom (2017-2028)
  • Figure 50: Age-Specific Diagnosed Prevalence of Chronic Lower Back Pain in the United Kingdom (2017-2028)
  • Figure 51: Severity-Specific Diagnosed Prevalence of CLBP in the UK (2017-2028)
  • Figure 52: Number of CLBP Patients on Prescription Medications by different Class in the UK (2017-2028)
  • Figure 53: Number of CLBP Patients on Opioids by low dose, high dose & Overdose in the UK (2017-2028)
  • Figure 54: Total Prevalent Population of Chronic Lower Back Pain in Japan (2017-2028)
  • Figure 55: Total Diagnosed Prevalent Population of Chronic Lower Back Pain in Japan (2017-2028)
  • Figure 56: Gender-Specific Diagnosed Prevalence of Chronic Lower Back Pain in Japan (2017-2028)
  • Figure 57: Age-Specific Diagnosed Prevalence of Chronic Lower Back Pain CLBP in Japan (2017-2028)
  • Figure 58: Severity-Specific Diagnosed Prevalence of CLBP in Japan (2017-2028)
  • Figure 59: Number of CLBP Patients on Prescription Medications by different Class in Japan (2017-2028)
  • Figure 60: Number of CLBP Patients on Opioids by low dose, high dose & Overdose in Japan (2017-2028)
  • Figure 61: The Vicious Circle showing the interaction of influencing factors
  • Figure 62: Treatment Algorithm for Chronic Low Back Pain
  • Figure 63: Unmet needs
  • Figure 64: Market Size of Chronic Lower Back Pain in the 7MM in USD Million (2017-2028)
  • Figure 65: Market Size of Chronic Lower Back Pain by therapies in the 7MM, in USD Million (2017-2028)
  • Figure 66: Market Size of Chronic Lower Back Pain in the US, USD Millions (2017-2028)
  • Figure 67: Market Size of Chronic Lower Back Pain by therapies in the United States, in USD Million (2017-2028)
  • Figure 68: Market Size of Chronic Lower Back Pain in Germany, USD Millions (2017-2028)
  • Figure 69: Market Size of Chronic Lower Back Pain by therapies in Germany, in USD Million (2017-2028)
  • Figure 70: Market Size of Chronic Lower Back Pain in France, USD Millions (2017-2028)
  • Figure 71: Market Size of Chronic Lower Back Pain by therapies in France, in USD Million (2017-2028)
  • Figure 72: Market Size of Chronic Lower Back Pain in Italy, USD Millions (2017-2028)
  • Figure 73: Market Size of Chronic Lower Back Pain by therapies in Italy in USD Million (2017-2028)
  • Figure 74: Market Size of Chronic Lower Back Pain in Spain, USD Millions (2017-2028)
  • Figure 75: Market Size of Chronic Lower Back Pain by therapies in Spain in USD Million (2017-2028)
  • Figure 76: Market Size of Chronic Lower Back Pain in the UK, USD Millions (2017-2028)
  • Figure 77: Market Size of Chronic Lower Back Pain by therapies in the UK in USD Million (2017-2028)
  • Figure 78: Market Size of Chronic Lower Back Pain in Japan, USD Millions (2017-2028)
  • Figure 79: Market Size of Chronic Lower Back Pain by therapies in Japan in USD Million (2017-2028)
  • Figure 80: Market Drivers
  • Figure 81: Market Barriers
目次
Product Code: DIMI0518

DelveInsight's 'Chronic Lower Back Pain (CLBP)- Market Insights, Epidemiology and Market Forecast-2028 report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology as well as the market trends of CLBP in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

The report provides the current treatment practices, emerging drugs, market share of the individual therapies, the current and forecasted market size of CLBP from 2017 to 2028 segmented by the seven major markets. The report also covers current treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate best of the opportunities and assess the underlying potential of the market.

Geography Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2017-2028

Chronic Lower Back Pain (CLBP) - Disease Understanding and Treatment Algorithm

Chronic low back pain (CLBP) is defined as pain that persists for 12 weeks or longer, even after an initial injury or underlying cause of acute low back pain has been treated. Low back pain is very common and at one point everyone may have faced this problem. The exact cause of lower back pain is unknown. Lower back pain that is long-term (for more than 3 months) is called chronic low back pain, this condition might originate from an injury, disease, or stress on different structures of the body, and pain may vary significantly and may be felt as bone pain, nerve pain, or muscle pain.

When assessing CLBP, clinicians should inquire about pain onset, severity, chronicity, and other factors such as painful experience. Pain severity may form a bi-dimensional or a one-dimensional scale depending on the specific instruments tested. High inter-correlations between pain-intensity measures and pain-related disability measures support the concept of using them as a unitary construct of pain severity. Various scales are used by experts in order to assess the severity of pain in CLBP patients, two of the most widely used are Visual Analogue Scale (VAS) and Verbal Rating Scale (VRS).

The DelveInsight's CLBP market report gives a thorough understanding of the CLBP by including details such as disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends. It also provides treatment algorithms and treatment guidelines for CLBP in the US, Europe, and Japan.

Chronic Lower Back Pain (CLBP) - Epidemiology

The CLBP epidemiology division provides insights about historical and current patient pool and forecasted trend for every 7 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight's report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology [segmented by Total Prevalent Population, Gender-Specific Prevalent Population, Age-Specific Prevalent Population, Severity-Specific Prevalent Population, Number of CLBP Patients on Prescription Medications by different Class and Number of CLBP Patients on Opioids by low dose, high dose, and overdose] scenario of CLBP in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom) and Japan from 2017 to 2028.

As per DelveInsight's analysis, a higher percentage of diagnosed prevalence was observed for females, in comparison to males, in all the 7MM countries, except Japan, wherein males occupy a larger patient pool than females. According to DelveInsight's estimations, the total prevalent population of CLBP in the 7MM was observed to be 73,802,461 in 2017, which is expected to increase during the study period i.e. 2017-2028. Furthermore, the total diagnosed prevalent population of CLBP in the 7MM was assessed to be 44,281,476 in 2017.

The estimates show the highest diagnosed prevalence of CLBP in the United States with more than 20 million cases in 2017. Among the European 5 countries, the United Kingdom had the highest diagnosed prevalent population of CLBP, followed by Germany and France. On the other hand, Spain had the lowest diagnosed prevalent population. Additionally, Japan was observed with 8,865,879 diagnosed prevalent cases for CLBP in 2017. According to DelveInsight's analysis, it has been observed that CLBP is mostly diagnosed in the age group of 40-69. Moreover, we have observed that moderate to severe are the majorly diagnosed CLBP patients.

Chronic Lower Back Pain (CLBP) - Drug Chapters

This segment of the CLBP report encloses the detailed analysis of marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

NKTR-181 (Nektar Therapeutics), a long-lasting opioids analgesic, acts as a selective mu-opioid receptor (MOR) agonist, is aimed to provide potent drug relief without the inherently high levels of euphoria. Phase III trial has been completed and another phase III trial currently under evaluation. NKTR-181 has been granted Fast Track designation by the US FDA and new drug application (NDA) has been filed for this drug by the company. NKTR-181 is the first analgesic opioid molecule to exhibit a reduction in specific CNS-mediated side effects, like euphoria, through the strategic alteration of brain-entry kinetics.

Buprenorphine (CAM2038: Braeburn Pharmaceuticals/Camurus) acts as a partial agonist at the mu opioid receptor and also exhibits antagonistic effects at the kappa opioid receptor. This drug is being evaluated in Phase III clinical trials Opioid Use Disorder; Chronic Pain, and Chronic Lower Back Pain. The company is expecting long-term efficacy and results of pivotal Phase III studies by the first half of 2019. The drug has an advantage in the administration as it is weekly/monthly SC depot, which avoids the healthcare professional requirement. If approved, CAM2038 offers an HCP-administered dosing regimen that will allow patients to transition from daily oral opioids to manage chronic pain, while potentially minimizing the risks of abuse, misuse, and diversion.

Egalet-002 (Egalet Corporation), is pure opioid which acts as opioid mu and kappa agonist; opioid delta agonists. The US FDA has granted Fast Track Designation for this drug. Eaglet Corporation has filed the NDA for this drug candidate. Egalet Corporation initially anticipated the NDA submission of Egalet-002 in 2019. Although the company completed phase III studies for Egalet-002 with proven efficacy, it has determined to delay indefinitely the previously-announced anticipated 2019 filing date for the Egalet-002 NDA, unless the availability of a partner to share the cost. The company is actively seeking partners for Egalet-002 as well as other product candidates.

Tanezumab (Pfizer/Eli Lilly and Company) is the first-in-class, non-opioids treatment which acts by selectively targeting, binding to and inhibiting nerve growth factor (NGF). The drug is being evaluated in Phase III clinical trials for CLBP. The US FDA has granted Fast Track designation for Tanezumab for the treatment of chronic pain in patients with osteoarthritis (OA) and CLBP. But a lower dose of the drug, tanezumab, failed to alleviate pain when compared with a placebo, the companies said in a statement.

Rexlemestrocel-L (MPC-06-ID; Mesoblast) is an allogeneic mesenchymal precursor cell (MPC) product candidate and Phase III trials are being conducted for this potent drug candidate. This drug works as "Cell Replacement: Proteoglycan & collagen stimulant".

Chronic Lower Back Pain (CLBP) - Market Outlook

The CLBP market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

This segment gives a thorough detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market, and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

A number of medications have proven to be effective in chronic pain disorders and their use individually or in combination should improve the management of chronic pain. Especially for neuropathic pain, the medications recommended as first-line treatments include TCAs, SNRIs, calcium channel α2-δ ligands, and lidocaine patch. Opioid analgesics and tramadol are recommended as second-line treatments that can be considered for first-line use in selected clinical circumstances.

A thorough understanding of pain mechanisms and good communication between physicians and patients are required to improve patient outcomes. Avoiding ineffective treatments and maximizing the treatments that have been proven beneficial in clinical trials (i.e., evidence-based treatments) are likely to produce better outcomes than have often been experienced by clinicians and patients in the management of chronic pain. Additionally, identifying and co-managing pain that is comorbid with psychiatric disorders have promise for improving both the physical and psychological outcomes.

Furthermore, the multimodality treatment of chronic pain incorporates not only this approach to pharmacological treatment, but also non-pharmacological strategies such as interventional pain management, physiotherapy, psychotherapy, and pain rehabilitation.

The market size of CLBP in the 7MM is expected to grow at a CAGR of 4.84% for the study period (2017-2028). The current market size of CLBP is entirely dependent on supportive treatment regimens, along with the drugs that have been approved to treat comorbidities associated with CLBP, and those that are in general approved for chronic pain. The supportive therapies are either prescribed as monotherapy or are given in combination. The prescription of these therapies varies greatly among the 7MM countries, i.e. while opioids remain the mainstay of treatment in the United States, NSAIDs are more commonly prescribed in the EU-5 countries.

With the launch of the effective branded targeted therapies, the market is going to rise which will introduce another USD 623.19 million in 2022, to the overall therapies market. Of the emerging therapies, Braeburn Pharmaceuticals/Camurus, Pfizer/Eli Lilly and Company, Mesoblast, Nektar Therapeutics, Egalet Corporation are expected to enter the treatment market, with their respective products, during the forecast period [2019-2028]. The current opioid prescription market is expected to decline in the coming years. This may be attributed to the fact that in the coming years, patients with CLBP will switch from currently prescribed opioids to emerging opioid therapies, such as, NKTR-181 (Nektar Therapeutics), Buprenorphine (CAM2038; Braeburn Pharmaceuticals/Camurus), and Egalet-002 (Egalet Corporation), which have proven safety and efficacy in CLBP patients.

Chronic Lower Back Pain (CLBP) - Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2017 to 2028. The analysis covers market uptake by drugs; patient uptake by therapies, and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

The dynamics of Chronic Lower Back Pain (CLBP) market is anticipated to change in the coming years owing to the improvement in the diagnosis methodologies, raising awareness of the diseases, incremental healthcare spending across the world and expected the launch of emerging therapies during the forecast period of 2019-2028. Companies across the globe are thoroughly working toward the development of new treatment therapies for CLBP.

More than a dozen companies have shifted their focus towards this therapeutic area. To name a few: Braeburn Pharmaceuticals, Camurus, Regeneron Pharmaceuticals, Teva Pharmaceutical, Pfizer, Eli Lilly and Company, Mesoblast, Nektar Therapeutics, Egalet Corporation, Axsome Therapeutics, Allodynic Therapeutics, Astellas Pharma, Grunenthal GmbH, Frontier Biotechnologies, DiscGenics, Yuhan Corporation, Semnur Pharmaceuticals, Sollis Therapeutics, SpineThera, Stayble Therapeutics, AnGes MG, and others. While some of these are in the early stage of development, yet others have reached the NDA filling stage in the development process.

CLBP Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Pipeline Analysis
  • Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

CLBP Report Key Strengths

  • 10 Years Forecast
  • 7MM Coverage
  • Epidemiology Segmentation
  • Key Cross Competition
  • Market Size by Therapies
  • Drugs Uptake

CLBP Report Assessment

  • Pipeline Product Profiles
  • Key Products and Key Players
  • Market Drivers and Barriers

Key Benefits

  • This DelveInsight report will help to develop Business Strategies by understanding the trends shaping and driving the CLBP market
  • Organize sales and marketing efforts by identifying the best opportunities for CLBP market
  • To understand the future market competition in the CLBP market.

Table of Contents

1. Key Insights

2. Chronic Lower Back Pain (CLBP) Market Overview at a Glance

  • 2.1. Market (%) Distribution of CLBP in 2017
  • 2.2. Market (%) Distribution of CLBP in 2028

3. Chronic Lower Back Pain (CLBP): Disease Background and Overview

  • 3.1. Introduction
  • 3.2. Signs and Symptoms
  • 3.3. Causes and Risk Factors
  • 3.4. Genetics of Chronic Lower Back Pain
  • 3.5. Pathophysiology
    • 3.5.1. Degenerative Cascade
    • 3.5.2. Mechanistic factors involved behind the cause of CLBP
    • 3.5.3. Neuroplasticity and central sensitization
    • 3.5.4. Connective tissue remodeling in CLBP
    • 3.5.5. Effect of connective tissue pathology on sensory afferent modulation
    • 3.5.6. CLBP and Connective Tissue Remodeling
    • 3.5.7. Pathophysiological model
  • 3.6. Type of pain
    • 3.6.1. Diskogenic pain
    • 3.6.2. Lumbar spinal stenosis
    • 3.6.3. Sacroiliac pain
    • 3.6.4. Facet-joint pain
    • 3.6.5. Radicular pain
    • 3.6.6. Muscular pain
  • 3.7. Diagnosis
    • 3.7.1. Clinical History
    • 3.7.2. Physical Examination
    • 3.7.3. Imaging Guidelines
    • 3.7.4. Assessment of Pain

4. Epidemiology and Patient Population

  • 4.1. Key Findings
  • 4.2. Total Prevalent Population of Chronic Lower Back Pain in the 7MM
  • 4.3. Total Diagnosed Prevalent Population of Chronic Lower Back Pain in the 7MM
  • 4.4. Gender-Specific Diagnosed Prevalence of Chronic Lower Back Pain in the 7MM
  • 4.5. Age-Specific Diagnosed Prevalence of Chronic Lower Back Pain in the 7MM
  • 4.6. Severity-Specific Diagnosed Prevalence of Chronic Lower Back Pain in the 7MM

5. United States Epidemiology

  • 5.1. Assumptions and Rationale
  • 5.2. Total Prevalent Population of Chronic Lower Back Pain in the United States
  • 5.3. Total Diagnosed Prevalent Population of Chronic Lower Back Pain in the United States
  • 5.4. Gender-Specific Diagnosed Prevalence of Chronic Lower Back Pain in the United States
  • 5.5. Age-Specific Diagnosed Prevalence of Chronic Lower Back Pain in the United States
  • 5.6. Severity-Specific Diagnosed Prevalence of CLBP in the United States
  • 5.7. Number of CLBP Patients on Prescription Medications by different Class in the United States
  • 5.8. Number of CLBP Patients on Opioids by low dose, high dose & Overdose in the United States

6. EU5 Epidemiology

  • 6.1. Germany Epidemiology
    • 6.1.1. Assumptions and Rationale
    • 6.1.2. Total Prevalent Population of Chronic Lower Back Pain in Germany
    • 6.1.3. Total Diagnosed Prevalent Population of Chronic Lower Back Pain in Germany
    • 6.1.4. Gender-Specific Diagnosed Prevalence of Chronic Lower Back Pain in Germany
    • 6.1.5. Age-Specific Diagnosed Prevalence of Chronic Lower Back Pain in Germany
    • 6.1.6. Severity-Specific Diagnosed Prevalence of CLBP in Germany
    • 6.1.7. Number of CLBP Patients on Prescription Medications by different Class in Germany
    • 6.1.8. Number of CLBP Patients on Opioids by low dose, high dose & Overdose in Germany
  • 6.2. France Epidemiology
    • 6.2.1. Assumptions and rationale
    • 6.2.2. Total Prevalent Population of Chronic Lower Back Pain in France
    • 6.2.3. Total Diagnosed Prevalent Population of Chronic Lower Back Pain in France
    • 6.2.4. Gender-Specific Diagnosed Prevalence of Chronic Lower Back Pain in France
    • 6.2.5. Age-Specific Diagnosed Prevalence of Chronic Lower Back Pain in France
    • 6.2.6. Severity-Specific Diagnosed Prevalence of CLBP in France
    • 6.2.7. Number of CLBP Patients on Prescription Medications by different Class in France
    • 6.2.8. Number of CLBP Patients on Opioids by low dose, high dose & Overdose in France
  • 6.3. Italy Epidemiology
    • 6.3.1. Assumptions and Rationale
    • 6.3.2. Total Prevalent Population of Chronic Lower Back Pain in Italy
    • 6.3.3. Total Diagnosed Prevalent Population of Chronic Lower Back Pain in Italy
    • 6.3.4. Gender-Specific Diagnosed Prevalence of Chronic Lower Back Pain in Italy
    • 6.3.5. Age-Specific Diagnosed Prevalence of Chronic Lower Back Pain in Italy
    • 6.3.6. Severity-Specific Diagnosed Prevalence of CLBP in Italy
    • 6.3.7. Number of CLBP Patients on Prescription Medications by different Class in Italy
    • 6.3.8. Number of CLBP Patients on Opioids by low dose, high dose & Overdose in Italy
  • 6.4. Spain Epidemiology
    • 6.4.1. Assumptions and Rationale
    • 6.4.2. Total Prevalent Population of Chronic Lower Back Pain in Spain
    • 6.4.3. Total Diagnosed Prevalent Population of Chronic Lower Back Pain in Spain
    • 6.4.4. Gender-Specific Diagnosed Prevalence of Chronic Lower Back Pain in Spain
    • 6.4.5. Age-Specific Diagnosed Prevalence of Chronic Lower Back Pain in Spain
    • 6.4.6. Severity-Specific Diagnosed Prevalence of CLBP in Spain
    • 6.4.7. Number of CLBP Patients on Prescription Medications by different Class in Spain
    • 6.4.8. Number of CLBP Patients on Opioids by low dose, high dose & Overdose in Spain
  • 6.5. United Kingdom Epidemiology
    • 6.5.1. Assumptions and Rationale
    • 6.5.2. Total Prevalent Population of Chronic Lower Back Pain in the United Kingdom
    • 6.5.3. Total Diagnosed Prevalent Population of Chronic Lower Back Pain in the United Kingdom
    • 6.5.4. Gender-Specific Diagnosed Prevalence of Chronic Lower Back Pain in the United Kingdom
    • 6.5.5. Age-Specific Diagnosed Prevalence of Chronic Lower Back Pain in the United Kingdom
    • 6.5.6. Severity-Specific Diagnosed Prevalence of CLBP in the United Kingdom
    • 6.5.7. Number of CLBP Patients on Prescription Medications by different Class in the United Kingdom
    • 6.5.8. Number of CLBP Patients on Opioids by low dose, high dose & Overdose in the United Kingdom

7. Japan Epidemiology

  • 7.1. Assumptions and Rationale
  • 7.2. Total Prevalent Population of Chronic Lower Back Pain in Japan
  • 7.3. Total Diagnosed Prevalent Population of Chronic Lower Back Pain in Japan
  • 7.4. Gender-Specific Diagnosed Prevalence of Chronic Lower Back Pain in Japan
  • 7.5. Age-Specific Diagnosed Prevalence of Chronic Lower Back Pain in Japan
  • 7.6. Severity-Specific Diagnosed Prevalence of CLBP in Japan
  • 7.7. Number of CLBP Patients on Prescription Medications by different Class in the Japan
  • 7.8. Number of CLBP Patients on Opioids by low dose, high dose & Overdose in the Japan

8. Treatment Algorithm, Current Treatment, and Medical Practices

  • 8.1. Non-pharmacological treatments
  • 8.2. Pharmacologic Treatments
    • 8.2.1. Non-opioids Analgesics
    • 8.2.2. Opioid Analgesics
    • 8.2.3. Tramadol W
    • 8.2.4. Antidepressants
    • 8.2.5. Muscle relaxants
  • 8.3. Treatment Algorithm

9. Proposed Guidelines for Chronic Lower Back Pain

  • 9.1. NICE Guidelines
    • 9.1.1. Recommendation
  • 9.2. Center of disease control and prevention (CDC) Guidelines
    • 9.2.1. Recommendations
  • 9.3. American College of Physicians (ACP) Guidelines
    • 9.3.1. Recommendations

10. Unmet Needs

11. Marketed Products

  • 11.1. Cymbalta (Duloxetine): Eli Lilly and Company
    • 11.1.1. Product Description
    • 11.1.2. Regulatory Milestones
    • 11.1.3. Clinical development
    • 11.1.4. Safety and Efficacy
    • 11.1.5. Advantages and disadvantages
    • 11.1.6. Product Profile
  • 11.2. Xtampza: Collegium Pharmaceutical
    • 11.2.1. Product Description
    • 11.2.2. Regulatory Milestones
    • 11.2.3. Clinical Development
    • 11.2.4. Safety and Efficacy
    • 11.2.5. Product Profile
  • 11.3. Butrans (buprenorphine): Purdue Pharma
    • 11.3.1. Product Description
    • 11.3.2. Regulatory Milestones
    • 11.3.3. Clinical Development
    • 11.3.4. Safety and Efficacy
    • 11.3.5. Product Profile
  • 11.4. Belbuca: BioDelivery Sciences International
    • 11.4.1. Product Description
    • 11.4.2. Regulatory Milestones
    • 11.4.3. Clinical Development
    • 11.4.4. Safety and Efficacy
    • 11.4.5. Product Profile

12. Emerging Therapies

  • 12.1. Key Cross Competition
  • 12.2. NKTR-181: Nektar Therapeutics
    • 12.2.1. Drug Description
    • 12.2.2. Other Developmental Activities
    • 12.2.3. Clinical Development
    • 12.2.4. Safety and Efficacy
    • 12.2.5. Product Profile
  • 12.3. Tanezumab: Eli Lilly/Pfizer
    • 12.3.1. Product Description
    • 12.3.2. Other Developmental Activities
    • 12.3.3. Clinical Development
    • 12.3.4. Safety and Efficacy
    • 12.3.5. Product Profile
  • 12.4. Fasinumab: Regeneron Pharmaceuticals/ Teva Pharmaceuticals
    • 12.4.1. Product Description
    • 12.4.2. Other Developmental Activities
    • 12.4.3. Clinical Development
    • 12.4.4. Safety and Efficacy
    • 12.4.5. Product Profile
  • 12.5. MPC-06-ID (Rexlemestrocel-L): Mesoblast
    • 12.5.1. Drug Description
    • 12.5.2. Other Developmental Activities
    • 12.5.3. Clinical Development
    • 12.5.4. Safety and Efficacy
    • 12.5.5. Product Profile
  • 12.6. CAM2038: Braeburn Pharmaceuticals/Camurus
    • 12.6.1. Drug Description
    • 12.6.2. Other Developmental Activities
    • 12.6.3. Clinical Development
    • 12.6.4. Safety and Efficacy
    • 12.6.5. Product Profile
  • 12.7. Egalet-002: Egalet Corporation
    • 12.7.1. Drug Description
    • 12.7.2. Other Developmental Activities
    • 12.7.3. Clinical Development
    • 12.7.4. Safety and Efficacy
    • 12.7.5. Product Profile
  • 12.8. ALLOD-2: Allodynic Therapeutics
    • 12.8.1. Drug Description
    • 12.8.2. Other Developmental Activities
    • 12.8.3. Clinical Development
    • 12.8.4. Product Profile
  • 12.9. Clonidine Micropellets (STX-051): Sollis Therapeutics
    • 12.9.1. Product Description
    • 12.9.2. Product Development Activities
    • 12.9.3. Clinical development
    • 12.9.4. Product Profile
  • 12.10. GRT6005: Grunenthal GmbH
    • 12.10.1. Drug Description
    • 12.10.2. Other Developmental Activities:
    • 12.10.3. Clinical Development
    • 12.10.4. Safety and Efficacy
    • 12.10.5. Product profile
  • 12.11. AB001: Frontier Biotechnologies
    • 12.11.1. Drug Description
    • 12.11.2. Other developmental activities
    • 12.11.3. Clinical Development
    • 12.11.4. Safety and efficacy
    • 12.11.5. Product profile
  • 12.12. ASP7962: Astellas Pharma Europe B.V.
    • 12.12.1. Drug Description
    • 12.12.2. Clinical Development
    • 12.12.3. Safety and Efficacy
    • 12.12.4. Product profile
  • 12.13. AXS-02 (disodium zoledronate tetrahydrate): Axsome Therapeutics
    • 12.13.1. Drug description
    • 12.13.2. Other Developmental activities
    • 12.13.3. Clinical Development
    • 12.13.4. Product Profile
  • 12.14. YH14618: Yuhan Corporation
    • 12.14.1. Drug description
    • 12.14.2. Other developmental activities
    • 12.14.3. Clinical development
    • 12.14.4. Product profile
  • 12.15. IDCT: DiscGenics
    • 12.15.1. Drug Description
    • 12.15.2. Other Developmental Activities
    • 12.15.3. Clinical Developmental Activities
    • 12.15.4. Safety and efficacy
    • 12.15.5. Product Profile
  • 12.16. SP-102: Semnur Pharmaceuticals
    • 12.16.1. Product Description
    • 12.16.2. Other Developmental Activities
    • 12.16.3. Clinical Development
    • 12.16.4. Safety and Efficacy
    • 12.16.5. Product Profile
  • 12.17. SX600: SpineThera
    • 12.17.1. Product Description
    • 12.17.2. Other Developmental Activities
    • 12.17.3. Clinical Development
    • 12.17.4. Product Profile

13. Chronic Lower Back Pain (CLBP): 7MM Market Analysis

  • 13.1. Key Findings
  • 13.2. Market Size of Chronic Lower Back Pain in 7MM
  • 13.3. Market Size of Chronic Lower Back Pain by Therapies in the 7MM
  • 13.4. Opioid Epidemic across the 7MM Countries

14. United States: Market Outlook

  • 14.1. United States Market Size
    • 14.1.1. Total Market size of Chronic Lower Back Pain in the United States
    • 14.1.2. Market Size of Chronic Lower Back Pain by Therapies in the US

15. EU-5 countries: Market Outlook

  • 15.1. Germany Market Size
    • 15.1.1. Total Market size of Chronic Lower Back Pain in Germany
    • 15.1.2. Market Size of Chronic Lower Back Pain by therapies in Germany
  • 15.2. France Market Size
    • 15.2.1. Total Market size of Chronic Lower Back Pain in France
    • 15.2.2. Market Size of Chronic Lower Back Pain by therapies in France
  • 15.3. Italy Market Size
    • 15.3.1. Total Market size of Chronic Lower Back Pain in Italy
    • 15.3.2. Market Size of Chronic Lower Back Pain by therapies in Italy
  • 15.4. Spain Market Size
    • 15.4.1. Total Market size of Chronic Lower Back Pain in Spain
    • 15.4.2. Market Size of Chronic Lower Back Pain by therapies in Spain
  • 15.5. United Kingdom Market Size
    • 15.5.1. Total Market size of Chronic Lower Back Pain in the United Kingdom
    • 15.5.2. Market Size of Chronic Lower Back Pain by therapies in the UK

16. Japan Market Outlook

  • 16.1. Japan Market Size
    • 16.1.1. Total Market size of Chronic Lower Back Pain in Japan
    • 16.1.2. Market Size of Chronic Lower Back Pain by therapies in Japan

17. Market Drivers

18. Market Barriers

19. Appendix

  • 19.1. Report Methodology

20. DelveInsight Capabilities

21. Disclaimer

22. About DelveInsight

Back to Top